DDR on DTC: Galderma's Oracea

Share this article:
Hooray for Galderma and their new campaign for Oracea (pronounced or-A–sha) that treats rosacea (pronounced roh-ZAY-sha). This is truly a brand that has been named, positioned and, now, promoted, with the perspective of the end user in mind—30-plus-year-old women who suffer from rosacea. 

In case you haven't heard of rosacea, it's sometimes called adult acne and affects about 13 million people with embarrassing red bumps and blemishes. Galderma's Oracea is the only oral treatment for rosacea, and they reinforce this with the use of a classic “demo” in TV spots that show how it works “from within.” These kinds of reassurances are important to help educate and convince sufferers most likely to be treating with a topical. 

This campaign stands out vs. most DTC because of its liveliness and, of course, the positive, upbeat animation. “Karen” looks in the mirror and doesn't like what she sees—until her “reflection” suggests she ask a doctor about Oracea. In just a few seconds, the campaign cleverly turns common insecurity about personal appearance into an empowering resolution. 

In one last stroke of advertising genius, the campaign reminds rosacea sufferers it's not their fault they have those red bumps on their faces by adding a subtle rhyming tagline, “Help discipline your skin…” Hooray—or maybe Hooracia—for Oracea!

Deborah Dick-Rath is SVP, healthcare practice leader, at FactorTG

Share this article:

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...